The technology – known RHEpatch - was originally designed as a programmable controlled-release delivery system for drugs used to treat central nervous system disorders like Alzheimer's and Parkinson’s disease.
However, the platform’s electronic delivery control system, coupled with its ability to delivery several different medications at the same time differentiate it out from other patches on the market according to Rhenovia.
The French firm told in-Pharmatechnologist.com that: “There are of course transdermal delivery systems or technologies that could administer two different products at the same time with a control of dose or administer several products contained in the same passive patch with multiple reservoirs.
“But, what is unique is that Rhepatch is the only technology having the capacity to initiate, control and interrupt the delivery at any time for up-to 7 products, to control the dose delivered and to harmonize the pharmacokinetics for a maximal efficacy.”
With this in mind the firm – which has already filed for patent protection in France – and Switzerland based development partner Portmann Instruments have created a prototype and completed proof-of-concept studies.
Now Rhenovia wants other companies to get involved.
“Rhenovia is looking for different types of partners to move the patch from the prototype stage to an industrial product or to sell licenses. Pharma or biotech companies which have capacity to bring a new product to market, patch manufacturers and other suppliers of individual components of RHEpatch.
The firm is also seeking financing partners for further developments, technological optimization, and proofs of pharmacokinetics harmonization for drugs combinations.